# CANF catalysts: Can-Fite BioPharma Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/canf/catalysts

> Can-Fite BioPharma Ltd. (CANF) has 5 upcoming catalysts. The next is the Can-Fite BioPharma Ltd. interim data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CANF?

Can-Fite BioPharma Ltd. (CANF) has 5 upcoming catalysts. The next is the Can-Fite BioPharma Ltd. interim data readout, Q1 2027. Press release filed with the SEC (EX-99): "The Company's lead drug candidate, Piclidenoson, is being evaluated in a pivotal Phase III study for the treatment of moderate-to-severe plaque psoriasis, which has completed enrollment of the first 247 patients for a pre-specified interim analysis, with interim efficacy and safety data expected in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/canf/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001213900-26-118358, https://www.sec.gov/Archives/edgar/data/1536196/000121390026118358/ea031201001ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/canf/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Can-Fite BioPharma Ltd. |
| Ticker | CANF (NYSE) |
| SEC CIK | 1536196 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/canf |

## Cash runway

Cash $5.5M as of 2025-12-31; quarterly burn $2.2M; about 7.4 months of runway at that rate (XBRL company facts, accession 0001213900-26-034447).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2022 | [Can-Fite BioPharma Ltd. topline data readout](https://sec-api.dev/companies/canf/catalysts) | CANF | moderate to serious psoriasis | completed, positive | "In June 2022, we announced positive top-line results from our Phase III COMFORT study of Piclidenoson in the treatment of moderate to serious psoriasis in which" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1536196/000121390025031298/ea0235093-20f_canfite.htm)) |
| March 24, 2025 | [Interleukin trial start](https://sec-api.dev/pdufa/interleukin) | CANF |  | completed | "BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it initiated a pivotal phase 3 psoriasis study of its oral drug" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1536196/000101376225001262/ea023536201ex99-1_canfite.htm)) |
| February 2026 | [Namodenoson primary completion](https://sec-api.dev/pdufa/namodenoson) | CANF | Hepatocellular Carcinoma; Cirrhosis | delayed | "NCT05201404 (Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-02 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05201404)) |
| Q3 2026 | [Can-Fite BioPharma Ltd. topline data readout](https://sec-api.dev/companies/canf/catalysts) | CANF |  | scheduled | "Dr. Sari Fishman, VP Business Development at Can-Fite, stated: "We are pleased with the successful completion of enrollment in this Phase 2 study and look forward to the upcoming data readout in Q3 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1536196/000121390026035956/ea028399301ex99-1.htm)) |
| Q3 2026 | [Can-Fite BioPharma Ltd. topline data readout](https://sec-api.dev/companies/canf/catalysts) | CANF |  | scheduled | "Top-line results are expected in the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1536196/000121390026035956/ea028399301ex99-1.htm)) |
| July 2026 | [Namodenoson primary completion](https://sec-api.dev/pdufa/namodenoson) | CANF | Pancreatic Adenocarcinoma; Pancreatic Cancer | delayed | "NCT06387342 (Namodenoson Treatment of Advanced Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-07-15 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06387342)) |
| Q4 2026 | [Can-Fite BioPharma Ltd. interim data readout](https://sec-api.dev/companies/canf/catalysts) | CANF |  | scheduled | "An interim analysis from the Phase III study is expected to be in approximately Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1536196/000121390025121959/ea026985501ex99-1_canfite.htm)) |
| Q1 2027 | [Can-Fite BioPharma Ltd. interim data readout](https://sec-api.dev/companies/canf/catalysts) | CANF | moderate-to-severe plaque psoriasis | scheduled | "The Company's lead drug candidate, Piclidenoson, is being evaluated in a pivotal Phase III study for the treatment of moderate-to-severe plaque psoriasis, which has completed enrollment of the first 247 patients for a pre-specified interim analysis, with interim efficacy and safety data expected in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1536196/000121390026118358/ea031201001ex99-1.htm)) |
| Aug to Nov 2027 | [Piclidenoson topline data readout](https://sec-api.dev/pdufa/piclidenoson) | CANF | Lowe Syndrome | scheduled | "NCT07410455 (An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07410455)) |
| August 2027 | [Piclidenoson primary completion](https://sec-api.dev/pdufa/piclidenoson) | CANF | Lowe Syndrome | scheduled | "NCT07410455 (An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07410455)) |
| December 2027 | [Piclidenoson primary completion](https://sec-api.dev/pdufa/piclidenoson) | CANF | Plaque Psoriasis | scheduled | "NCT06643260 (A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643260)) |
| Dec 2027 to Mar 2028 | [Piclidenoson topline data readout](https://sec-api.dev/pdufa/piclidenoson) | CANF | Plaque Psoriasis | scheduled | "NCT06643260 (A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643260)) |

## Drugs

- [Namodenoson](https://sec-api.dev/pdufa/namodenoson): Pancreatic Adenocarcinoma, Hepatocellular Carcinoma
- [Piclidenoson](https://sec-api.dev/pdufa/piclidenoson): Lowe Syndrome, Plaque Psoriasis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/canf/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CANF catalysts: Can-Fite BioPharma Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/canf/catalysts

```bibtex
@misc{secapidev_companies_canf_catalysts_20261116,
  title        = {CANF catalysts: Can-Fite BioPharma Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/canf/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_canf_catalysts_20261116","title":"CANF catalysts: Can-Fite BioPharma Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/canf/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
